CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Dimerix Bioscience Pty Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Dimerix Bioscience Pty Ltd
L 11 63 Exhibition Street
Melbourne, VIC  3000  Australia Fax: +61 893555694f:+61 893555694

This company was Merged or Acquired on 7/3/2015.
This is a Subsidiary, click here for the Parent Company

Business Summary
Dimerix Bioscience Pty Ltd, formerly Dimerix Bioscience Limited (Dimerix), is an Australia-based clinical-stage drug discovery and development company. The Company is engaged in developing and commercializing drug therapies. The Company's lead clinical program is a Phase II study in chronic kidney disease, DMX-200. Dimerix's DMX-200 is a treatment for persistent proteinuria (abnormally high levels of protein in the urine) caused by chronic kidney disease. In addition to the development of DMX200, the Company has used the information derived from the use of its Receptor-Heteromer Investigation Technology (Receptor-HIT) technology to select combination therapies. Applying Receptor-HIT technology to receptors, such as G-protein coupled receptors (GPCR's), Dimerix is able to identify differences in signaling behavior when receptors interact as heteromers. It has identified over 60 GPCR heteromers.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-------

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/20136/30/2013Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the Board James H.Williams 45 8/1/2006 8/1/2006
Chief Financial Officer, Company Secretary Ian R.Hobson
Chief Operating Officer Kathryn M.Harrison
5 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 126,103,000 (As of 6/17/2014)
Stock Exchange: ASX
Fax Number: +61 893555694


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023